Male hypogonadism and MAR IgG antibodies linked to type 1 diabetes mellitus in a South American cohort.

15 October 2023, Version 1
This content is an early or alternative research output and has not been peer-reviewed by Cambridge University Press at the time of posting.

Abstract

Objective. Evaluation of the pathogenic factor of autoimmune hypogonadism in men with a positive MAR IgG test result and type 1 diabetes mellitus (DM1) in a South American cohort. Materials and Methods. The retrospective study included 97 men with a positive MAR IgG test result: 30 patients with T1DM and 67 men without diabetes. The examination included determination of total testosterone and titer of antibodies against steroid-producing cells of reproductive tissue. Differences were considered statistically significant when p<0.05. Results.The incidence of high titers of autoantibodies against steroid-producing cells (Leydig cells) of the testes (CPT) in patients with T1DM and a positive MAR test is statistically significantly higher than in people without diabetes. In both groups, testosterone levels were statistically significantly lower with an increased CPT titer than with a normal titer. The incidence of hypogonadism in men with a high CPT titer was statistically significantly higher than in patients with a normal titer. Conclusion. Autoimmune hypogonadism is a common complication in men with T1DM and a positive MAR IgG test result and is associated with the formation of antibodies against steroid-producing cells of the reproductive tissue.

Keywords

Hypogonadism
Men
Autoinmune
Testosterone
Diabetes mellitus

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting and Discussion Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.